ALK (anaplastic lymphoma kinase)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Published in Atlas Database: September 1997

Online version is available at: http://AtlasGeneticsOncology.org/Genes/ALK.html

DOI: 10.4267/2042/32020

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.

© 1997 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Location: 2p23

DNA/RNA

*Transcription*

6.2 kb mRNA; coding sequence: 4.9 kb.

Protein

*Description*

1620 amino acids; 177 kDa; after glycosylation, produces a 200 kDa mature glycoprotein.

*Expression*

Tissue specific; mainly in: brain, gut and testis; not in the lymphocytes.

*Localisation*

Cell membrane.

*Function*

Membrane associated tyrosine kinase receptor; probable role in nervous system development and maintenance.

*Homology*

Homologies with the insulin receptor super family: LTK (leucocyte tyrosine kinase), TRKA, ROS (homolog of the drosophila Sevenless), IGF1-R and IRbeta.

Implicated in

\[ t(2;5)(p23;q35)/CD30+ \text{ NHL } \rightarrow \text{ NPM1/ALK} \]

Disease

High grade NHL; most often: CD30+ anaplastic large cell type.

Prognosis

Nonetheless, a 80% five yr survival may be associated with this anomaly.

Cytogenetics

Additional anomalies are most often found.

Hybrid/Mutated Gene

5' NPM1-3' ALK on der(5).

Abnormal Protein

680 amino acids; N-term NPM1 is fused to the 563 C-term aminoacids of ALK (i.e. the entire cytoplasmic portion of ALK); no apparent expression of the ALK/NPM1 counterpart; localisation: both in the cytoplasm and in the nucleus.

Oncogenesis

Via the kinase function activated by oligomerization of NPM1-ALK mediated by the NPM1 part.

References


This article should be referenced as such: